EIDON salus at SIME 2024 at “La Nuvola” in Rome
The 45th Congress of the Italian Society of Aesthetic Medicine took place in Rome from May 10th to 12th. EIDON Salus, present among the exhibitors, showcased its latest products: ROSEHA(the facial serum), OSIDRA (the only sublingual hyaluronic acid with two molecular weights) and LOVIDRA (a daily skincare routine for vulvovaginal health and beauty).
Attendance at the congress, which targeted industry professionals, was the highest ever. Indeed, not coincidentally the organizers moved the seat from the historic Hilton Hotel to the new and futuristic “La Nuvola” Conference Center, offering more space and comfort.
EIDON Salus may not be a multinational corporation, and its stand was not among the largest or most luxurious; however it was one of the most visited by curious doctors, mainly due to one product: OSIDRA, the sublingual hyaluronic acid product that distinguished itself in the field of health, wellness, and beauty.
OSIDRA contains hydrolyzed hyaluronic acid with two molecular weights: one very low to activate cellular metabolism and stimulate the production of new hyaluronic acid and collagen. The other is very high to attract large amounts of water, providing deep and intensive hydration.
The significant innovation of OSIDRA lies in its biotechnologies, which are entirely natural and allow for 100% bioavailability. This means the product is fully assimilated by the body with nothing wasted, thanks to sublingual absorption.
The peculiarity and innovation of OSIDRA were highly appreciated by specialists in Aesthetic Medicine and Gynecology, as its benefits extend to the skin, hair, eyes, and vaginal mucous membranes. It is an anti-aging product for the entire body.
The newly launched ROSEHA treatment for the face, eye area, neck, and décolleté was also very highlighted. The product has active peptides with a botox-like effect, cutting-edge 3D hyaluronic acid, and stem cells from Vitis vinifera and Rosa canina.
LOVIDRA, a cosmeceutical for the health and beauty of the vulvovaginal area, gained much interest as well.
EIDON Salus’s presence at SIME 2024 was certainly a success, attracting numerous proposals for clinical studies and collaborations with major Italian universities.
